Remarkably, SIAIS562055 effectively degraded SOS1 protein, inhibited ERK phosphorylation, and exhibited antiproliferative activity in primary CML samples spanning three distinct disease phases, despite doses higher than those required for imatinib therapy in cell lines. The gene discussed is MAPK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.